Lycia Therapeutics Raises $75 Million in Oversubscribed Financing and Strengthens Leadership Team with Appointment of Chief Financial Officer and General Counsel

Lycia Therapeutics completed an oversubscribed $75 million Series D financing round co-led by Janus Henderson Investors and Balyasny Asset Management. The company appointed Amy Bachrodt as CFO and promoted Karen Flick to General Counsel. Proceeds will support clinical development of LCA-0061 for food allergy and LCA-0321 for Graves' disease.